Response to “Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis’”
- Rand, K.
- Ramos-Goñi, J.M.
- Akmaz, B.
- Solé-Feu, L.
- Armario-Hita, J.-C.
ISSN: 2190-9172, 2193-8210
Año de publicación: 2024
Volumen: 14
Número: 3
Páginas: 823-827
Tipo: Carta
